 |
|
Risk of Lymphoma in Autoimmune Rheumatic Conditions
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We read with great interest the work of Zintzaras et al1 in their secondary analyses of cancer outcome in autoimmune rheumatic conditions including systemic lupus erythematous (SLE). Recently, the Systemic Lupus International Collaborating Clinics, in conjunction with the Canadian Network of Improved Outcomes in Systemic Lupus, published an international cohort study of cancer in SLE with 23 centers, with a total sample size of 9547 (an unprecedented number for epidemiologic research in SLE). For all cancers combined, the standardized incidence ratio estimate was 1.15 (95% confidence interval [CI], 1.05-1.27); for all hematologic malignancies, it was 2.75 (95% CI, 2.13-3.49); and for non-Hodgkin lymphoma (NHL), it was 3.64 (95% CI, 2.63-4.93). This thus provides, we believe, the most precise estimates generated to date for NHL occurrence in SLE.2
We are currently conducting a case-cohort study of the malignancies in this multicenter cohort, determining the effect of medications and other factors on . . . [Full Text of this Article]
AUTHOR INFORMATION
Sasha Bernatsky, MD, PhD;
Ann Clarke, MD, MSc;
Rosalind Ramsey-Goldman, MD, DrPH
RELATED ARTICLES
Risk of Lymphoma in Autoimmune Rheumatic Conditions—Reply
Elias Zintzaras, Michael Voulgarelis, and Haralampos M. Moutsopoulos
Arch Intern Med. 2006;166(11):1234.
EXTRACT
| FULL TEXT
The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-analysis
Elias Zintzaras, Michael Voulgarelis, and Haralampos M. Moutsopoulos
Arch Intern Med. 2005;165(20):2337-2344.
ABSTRACT
| FULL TEXT
|
